A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.
Subject: Schizophrenia - PUBLISHED VIA Current Pharmaceutical Design
Author(s):
Zuardi AW, Crippa JA, Hallak JE, Bhattacharyya S, Atakan Z, Martin-Santos R, McGuire PK, Guimarães FS
View Source >>
Related Studies:
Medical use of cannabis. Cannabidiol: a new light for schizophrenia?
Published via Drug Testing and Analysis
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
Published via Brazilian Journal of Medical and Biological Research
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.
Published via Translational Psychiatry
Cannabidiol as a potential treatment for psychosis.
Published via European Neuropsychopharmacology
Peripheral endocannabinoid system dysregulation in first-episode psychosis.
Published via Neuropsychopharmacology